TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 173 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2021. The put-call ratio across all filers is 4.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $2,954,000 | -27.7% | 44,467 | -15.1% | 0.06% | -26.3% |
Q2 2021 | $4,084,000 | -12.6% | 52,351 | +5.9% | 0.08% | -23.2% |
Q1 2021 | $4,674,000 | -55.5% | 49,413 | -42.7% | 0.10% | -58.1% |
Q4 2020 | $10,515,000 | +26.7% | 86,294 | -9.1% | 0.24% | -16.3% |
Q3 2020 | $8,296,000 | – | 94,964 | – | 0.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |